Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
4.300
-0.500 (-10.42%)
Aug 11, 2025, 2:06 PM - Market open
Everbridge Revenue
Agenus had revenue of $24.07M in the quarter ending March 31, 2025, a decrease of -14.07%. This brings the company's revenue in the last twelve months to $99.52M, down -38.34% year-over-year. In the year 2024, Agenus had annual revenue of $103.46M, down -33.81%.
Revenue (ttm)
$99.52M
Revenue Growth
-38.34%
P/S Ratio
1.09
Revenue / Employee
$314,949
Employees
316
Market Cap
117.89M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AGEN News
- 6 hours ago - Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress - Business Wire
- 11 days ago - Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report - Business Wire
- 17 days ago - Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 - Business Wire
- 5 weeks ago - Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3 - Business Wire
- 7 weeks ago - Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology - Business Wire
- 2 months ago - Agenus Announces Virtual Annual Shareholders Meeting - Business Wire
- 2 months ago - Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang - Benzinga
- 2 months ago - Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US - Business Wire